retrospect
cohort
studi
includ
patient
first
receiv
transplant
decemb
decemb
fred
hutchinson
cancer
research
center
fhcrc
document
piv
infect
hct
virolog
diagnos
univers
washington
virolog
laboratori
subset
patient
includ
previous
publish
report
individu
first
episod
piv
infect
analyz
patient
demograph
data
transplant
inform
closest
piv
infect
retriev
fhcrc
databas
data
relat
clinic
cours
piv
infect
collect
medic
record
review
studi
approv
institut
review
board
fhcrc
piv
detect
perform
convent
cultur
direct
fluoresc
antibodi
test
andor
revers
transcript
polymeras
chain
reaction
rtpcr
assay
respiratori
sampl
piv
upper
respiratori
tract
infect
urti
defin
piv
detect
nasopharyng
sputum
sampl
urti
symptom
new
pulmonari
infiltr
lrtd
divid
group
possibl
probabl
proven
possibl
lrtd
defin
piv
detect
nasopharyng
sputum
sampl
new
pulmonari
infiltr
without
confirm
piv
lower
respiratori
tract
without
lrtd
sign
symptom
eg
cough
wheez
rale
tachypnea
short
breath
dyspnea
hypoxia
probabl
lrtd
defin
piv
detect
bronchoalveolar
lavag
bal
lung
biopsi
sampl
lrtd
symptom
without
pulmonari
function
declin
without
new
pulmonari
infiltr
definit
proven
lrtd
piv
detect
bal
biopsi
sampl
new
pulmonari
infiltr
without
lrtd
symptom
viral
load
determin
quantit
rtpcr
use
store
frozen
repositori
sampl
peak
steroid
dose
record
period
within
week
piv
infect
patient
urti
piv
lrtd
case
peak
steroid
dose
record
within
week
lrtd
diagnosi
respect
exact
steroid
dose
month
diagnosi
also
collect
death
caus
respiratori
failur
defin
death
caus
exclus
predominantli
respiratori
failur
patient
demograph
characterist
summar
compar
among
diseas
categori
use
fisher
exact
test
categor
variabl
wilcoxon
ranksum
test
continu
variabl
appropri
wilcoxon
ranksum
kruskalw
test
util
comparison
continu
variabl
probabl
overal
surviv
estim
use
kaplanmei
method
probabl
mortal
caus
respiratori
failur
incid
mechan
ventil
estim
cumul
incid
curv
treat
death
due
caus
compet
risk
event
logrank
test
use
compar
univari
hazard
timetoev
outcom
diseas
categori
cox
proport
hazard
model
use
evalu
unadjust
adjust
hazard
ratio
hr
mortal
respiratori
mortal
associ
confid
interv
ci
report
variabl
p
univari
model
candid
multivari
model
twosid
p
valu
consid
statist
signific
total
patient
piv
infect
follow
hct
urti
lrtd
diseas
respect
lrtd
classif
patient
includ
possibl
probabl
proven
case
lrtd
characterist
piv
infect
group
shown
tabl
median
time
piv
infect
piv
lrtd
hct
day
rang
day
day
rang
respect
probabl
overal
surviv
mortal
respiratori
failur
day
follow
piv
diagnosi
patient
urti
lrtd
shown
figur
overal
surviv
urti
lrtd
mortal
respiratori
failur
urti
lrtd
p
comparison
next
analyz
probabl
overal
surviv
death
caus
respiratori
failur
among
lrtd
case
compar
diseas
categori
possibl
probabl
proven
figur
probabl
surviv
piv
lrtd
possibl
probabl
proven
case
respect
p
figur
presenc
lrtd
symptom
possibl
proven
case
result
wors
surviv
lrtd
symptom
present
supplementari
dataa
mortal
rate
group
shown
tabl
univari
analysi
risk
factor
overal
mortal
demonstr
probabl
proven
lrtd
significantli
associ
higher
mortal
compar
urti
hazard
ratio
hr
confid
interv
ci
p
probabl
case
hr
ci
p
proven
case
wherea
possibl
lrtd
hr
ci
p
similar
result
obtain
univari
analysi
risk
factor
mortal
respiratori
failur
hr
ci
p
possibl
case
hr
ci
p
probabl
case
hr
ci
p
proven
case
patient
possibl
lrtd
probabl
lrtd
die
day
diagnosi
feasibl
evalu
impact
diseas
categori
mortal
multivari
analys
probabl
requir
mechan
ventil
day
piv
lrtd
possibl
probabl
proven
case
respect
p
figur
oxygenfre
day
group
shown
tabl
day
aliv
without
hospit
day
piv
lrtd
longer
order
possibl
probabl
proven
case
mean
sd
day
possibl
case
sd
day
probabl
case
sd
day
proven
case
respect
p
focus
proven
probabl
lrtd
case
analyz
risk
factor
mortal
univari
analysi
risk
factor
overal
mortal
show
day
transplant
piv
infect
oxygen
use
cell
count
steroid
dose
mgkgday
diagnosi
signific
risk
factor
tabl
risk
factor
well
piv
type
also
signific
mortal
respiratori
failur
tabl
among
white
blood
cell
popul
monocyt
count
identifi
import
factor
mortal
multivari
analysi
tabl
result
similar
obtain
patient
proven
lrtd
except
low
monocyt
count
becom
signific
risk
factor
overal
mortal
multivari
analysi
adjust
hr
ahr
ci
p
lower
monocyt
count
statist
signific
effect
overal
surviv
risk
pulmonari
death
analyz
combin
oxygen
requir
diagnosi
figur
statist
signific
differ
mortal
seen
probabl
proven
lrtd
symptom
tabl
presenc
clinic
lrtd
symptom
tend
associ
wors
outcom
although
effect
reach
statist
signific
tabl
univari
analysi
steroid
dose
mgkgday
diagnosi
piv
lrtd
significantli
associ
increas
mortal
wherea
steroid
dose
mgkgday
dosedepend
effect
mortal
tabl
small
number
patient
receiv
steroid
dose
mgkgday
die
day
diagnosi
effect
steroid
dose
evalu
adjust
oxygen
requir
diagnosi
import
risk
factor
mortal
adjust
model
steroid
dose
mgkgday
diagnosi
remain
significantli
associ
mortal
tabl
use
ribavirin
significantli
associ
reduc
overal
mortal
mortal
respiratori
failur
multivari
analys
tabl
among
patient
proven
lrtd
howev
ribavirin
affect
overal
respiratori
mortal
ahr
ci
p
overal
mortal
ahr
ci
p
respiratori
mortal
highdos
intraven
immunoglobulin
ivig
also
effect
mortal
piv
lrtd
tabl
among
provenprob
lrtd
case
patient
diagnos
use
pcr
alon
although
patient
diagnos
pcr
alon
lower
viral
load
p
supplementari
dataa
statist
signific
surviv
advantag
tabl
provenprob
lrtd
case
store
bal
sampl
avail
test
quantit
rtpcr
statist
signific
differ
median
viral
load
subject
proven
probabl
lrtd
tabl
supplementari
datab
associ
viral
load
mortal
piv
lrtd
observ
even
adjust
oxygen
use
diagnosi
hr
ci
p
overal
mortal
hr
ci
p
mortal
respiratori
failur
tabl
data
shown
studi
demonstr
clinic
outcom
patient
piv
detect
lung
term
proven
probabl
lrtd
significantli
wors
patient
piv
detect
upper
respiratori
tract
sampl
term
possibl
lrtd
figur
outcom
patient
possibl
lrtd
similar
urti
studi
also
defin
import
clinic
risk
factor
associ
poor
outcom
piv
lrtd
includ
oxygen
requir
diagnosi
low
monocyt
count
steroid
use
mgkgday
numer
studi
respiratori
virus
immunocompromis
host
examin
lrtd
either
endpoint
risk
factor
mortal
howev
previous
publish
result
incid
risk
factor
progress
outcom
vari
wide
data
present
suggest
varianc
definit
lrtd
one
import
reason
observ
differ
address
issu
conduct
present
studi
defin
optim
diagnost
criteria
correl
outcom
base
site
virolog
detect
clinic
manifest
classifi
lrtd
group
possibl
probabl
proven
recent
publish
fourth
european
confer
infect
leukaemia
guidelin
also
propos
classif
base
level
certainti
possibl
probabl
confirm
howev
classif
respiratori
virus
appli
utri
lrtd
use
symptom
exposur
viral
detect
independ
site
classifi
contrast
classif
strictli
among
lrtd
case
virolog
confirm
paper
specif
focus
possibl
categori
includ
patient
nasopharyng
test
demonstr
piv
infect
abnorm
chest
radiographi
without
confirm
viru
lower
respiratori
tract
numer
public
well
societi
guidelin
gener
accept
patient
lrtd
data
demonstr
mortal
patient
possibl
lrtd
significantli
better
patient
probabl
proven
diseas
figur
similar
patient
urti
tabl
effect
persist
throughout
studi
period
data
shown
interestingli
possibl
lrtd
patient
without
symptom
tend
even
better
outcom
urti
supplementari
data
nevertheless
mani
studi
includ
categori
lrtd
therefor
suggest
group
defin
possibl
lrtd
separ
patient
group
viral
detect
lung
proven
probabl
lrtd
case
develop
definit
priori
base
clinic
practic
across
center
spectrum
definit
use
literatur
possibl
proven
categori
far
common
categori
document
seri
elsewher
bronchoscopi
base
piv
detect
upper
respiratori
tract
presenc
lrtd
symptom
signific
sign
obstruct
spirometri
probabl
categori
perform
center
becom
uncommon
recent
year
nevertheless
patient
inform
outcom
appear
similar
seen
proven
case
although
studi
focus
patient
infect
piv
hypothes
outcom
differ
seen
among
possibl
diseas
categori
may
also
exist
respiratori
virus
inde
studi
guidelin
nonpiv
respiratori
virus
includ
possibl
case
definit
lrtd
addit
studi
need
extend
result
respiratori
viru
infect
decad
ago
european
organ
research
treatment
cancerinvas
fungal
infect
cooper
group
nation
institut
allergi
infecti
diseas
mycos
studi
group
eortcmsg
establish
standard
definit
invas
fungal
diseas
guidelin
wide
accept
result
improv
reproduc
studi
result
center
guidelin
greatli
aid
consensu
endpoint
definit
clinic
trial
invas
fungal
diseas
new
drug
respiratori
virus
includ
piv
eg
advanc
clinic
develop
care
consider
lrtd
definit
correl
outcom
import
clinic
trial
endpoint
entri
criteria
stratif
variabl
anoth
novel
observ
studi
monocyt
count
diagnosi
lrtd
appear
critic
surviv
piv
lrtd
previou
studi
respiratori
viral
infect
immunocompromis
host
suggest
lymphocyt
neutrophil
import
cell
compon
mortal
studi
howev
lymphocyt
count
appear
less
import
monocyt
neutrophil
count
monocyt
seem
compris
import
cell
compon
tabl
inde
patient
monocytopen
requir
oxygen
diagnosi
lrtd
particularli
high
mortal
figur
monocyt
known
import
protect
viral
infect
neutrophil
may
also
import
role
time
pneumonia
cell
interact
data
basic
research
support
find
monocyt
neutrophil
import
outcom
lrtd
first
outcom
studi
piv
use
multivari
model
evalu
treatment
strategi
previou
studi
suggest
steroid
use
associ
high
mortal
result
show
steroid
use
mgkgday
piv
lrtd
associ
mortal
base
result
highdos
steroid
acut
lung
injuri
recommend
rapid
taper
steroid
graftvshost
diseas
may
requir
lower
dose
use
antivir
drug
current
approv
treatment
piv
diseas
ribavirin
ivig
often
use
offlabel
piv
lrtd
case
previou
report
show
conflict
result
rang
appar
efficaci
mortal
piv
lrtd
moder
efficaci
studi
small
sampl
size
statist
adjust
made
diseas
sever
thu
effect
ribavirin
still
controversi
result
show
conflict
result
ribavirin
treatment
although
overal
mortal
model
suggest
surviv
benefit
among
patient
proven
probabl
lrtd
tabl
signific
effect
seen
death
due
respiratori
failur
patient
proven
lrtd
import
variabl
highdos
steroid
effect
combin
therapi
ivig
could
adequ
assess
due
small
number
patient
provenprob
lrtd
receiv
treatment
combin
recent
pcr
test
becom
wide
util
diagnost
method
frequenc
diagnos
viral
infect
increas
howev
associ
quantit
rna
viral
load
mortal
piv
lrtd
well
evalu
studi
bal
sampl
also
posit
convent
method
gener
higher
viral
load
supplementari
dataa
consist
previou
report
nasal
wash
sampl
result
also
show
proven
probabl
diseas
categori
differ
regard
viral
load
presenc
clinic
lrtd
symptom
associ
higher
viral
load
supplementari
datab
find
provid
support
combin
group
outcom
analys
propos
studi
result
identifi
rna
viral
load
bal
signific
factor
mortal
although
number
subject
avail
viral
load
rel
small
studi
sever
limit
although
studi
largest
cohort
confirm
piv
infect
hct
recipi
includ
previous
report
case
well
subsequ
case
sampl
size
still
suffici
perform
multivari
analys
evalu
impact
lrtd
diseas
categori
effect
combin
sever
drug
mortal
retrospect
natur
studi
bal
sampl
avail
half
patient
viral
load
quantif
limit
multivari
model
use
bronchoscopi
workup
lrtd
larg
base
protocol
center
almost
patient
undergo
procedur
radiograph
sign
lrtd
symptom
occur
nevertheless
final
decis
perform
bronchoscopi
rest
attend
physician
patient
may
undergon
procedur
therefor
probabl
proven
case
may
miss
unlik
affect
major
result
studi
conclus
data
demonstr
patient
piv
detect
lung
provenprob
lrtd
wors
outcom
compar
piv
detect
nasopharyng
sampl
alon
possibl
lrtd
outcom
possibl
lrtd
compar
urti
lrtd
definit
could
use
futur
outcom
studi
independ
viru
type
studi
need
valid
result
virus
immunocompromis
host
set
consensu
definit
accord
outcom
develop
respiratori
viral
diseas
